Evidence map›Paper›PMID 39339293›Full record

ArticleMolecules (Basel, Switzerland)2024

Computational Exploration of the Mechanism of Action of a Sorafenib-Containing Ruthenium Complex as an Anticancer Agent for Photoactivated Chemotherapy.

Pierraffaele Barretta, Fortuna Ponte, Daniel Escudero, Gloria Mazzone

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Pierraffaele BarrettaDepartment of Chemistry and Chemical Technologies, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy.ORCID 0009-0009-7467-8387
Fortuna PonteDepartment of Chemistry and Chemical Technologies, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy.
Daniel EscuderoDepartment of Chemistry, KU Leuven, Celestijnenlaan 200F, 3001 Heverlee, Belgium.
Gloria MazzoneDepartment of Chemistry and Chemical Technologies, University of Calabria, Via P. Bucci, 87036 Rende (CS), Italy.ORCID 0000-0002-4686-6876

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruthenium(II) polypyridyl complexes are being tested as potential anticancer agents in different therapies, which include conventional chemotherapy and light-activated approaches. A mechanistic study on a recently synthesized dual-action Ru(II) complex [Ru(bpy)

Indexed as

Antineoplastic AgentsCoordination ComplexesRutheniumSorafenibHumansPhotochemotherapyPhotosensitizing AgentsAntineoplastic AgentsCoordination ComplexesPhotosensitizing AgentsRutheniumSorafenibISCPACTPDTphotosensitizerruthenium complexessorafenib

Identifiers

PMID39339293
PMCPMC11433670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.